Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients

Saroglitazar is a dual PPAR α/γ agonist approved in India for the management of diabetic dyslipidemia. AIMS: The objective of this study was to evaluate the safety and efficacy of saroglitazar 4 mg once daily in clinical practice. METHODS: This was an observational, multicenter, single-arm study. Pa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Indian Heart J
Hauptverfasser: Shetty, Sadanand R., Kumar, Soumitra, Mathur, R.P., Sharma, Kamal H., Jaiswal, Ashok D.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2015
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4382542/
https://ncbi.nlm.nih.gov/pubmed/25820046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ihj.2015.02.007
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge